Seeking Alpha covers Starpharma
|
Online stock market insights and research publication Seeking Alpha covered Starpharma’s Phase 3 results for VivaGel® BV for the treatment of recurrent bacterial vaginosis and noted the “substantial upside” of the announcement. To view the article, click here. |
Starpharma and Monash awarded STEM+ Business fellowships
|
Biotech news and industry publication Biotech Dispatch covered the news that Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) were awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding allows both Starpharma and Monash to further advance collaborative programs utilising Starpharma’s DEP platform. To view the article, click here. |
Hope is on the way for one of the world’s most common sexual problems
Investor publication Stockhead recently covered Starpharma’s VivaGel® BV Phase 3 announcement for prevention of recurrent bacterial vaginosis (rBV). The publication noted the significant unmet patient need for BV treatments and how VivaGel® BV targets one of the most common vaginal conditions affecting women of childbearing age.
Go to article (external link)
Starpharma readies US NDA for VivaGel® on positive results in Phase 3 Bacterial vaginosis
Biotech trade publication noted Starpharma expects to file an NDA for VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) with the US FDA following the positive results of the Phase 3 trials.
Starpharma and Monash awarded STEM+ Business Fellowships
Starpharma today announced that Starpharma and Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows.
Successful VivaGel® Phase 3 results and NDA planned for rBV
Starpharma today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data.
Biotech clinical trials a star performer
Herald Sun covered the investor interest in Starpharma following the positive results of the company’s VivaGel® BV Phase 3 clinical trials for the prevention of recurrent bacterial vaginosis (rBV). Starpharma CEO Dr Jackie Fairley noted VivaGel® BV demonstrated sustained benefits for patients three months after their initial treatment, positioning the company to unlock a multi-million dollar global market.
Go to article (external link)
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2017.
Shareholder Update July 2017
In this issue:
>> Starpharma sells Agrochemicals business to Agrium for $35M cash
>> DEP® irinotecan outperforms irinotecan in multiple cancer models
>> DEP® docetaxel, DEP® cabazitaxel and scale-up facilities
>> AstraZeneca pays US$2M DEP® milestone to Starpharma
>> VivaGel® BV phase 3 results timing and commercialisation
>> VivaGel® condom launched in Canada
>> Sale of Ansell's Sexual Wellness division
>> Starpharma News & Events
Download: Shareholder Update July 2017 (pdf file, 710kb)
VivaGel® BV phase 3 results timing and commercialisation
Starpharma today announced revised timing for results of its two pivotal VivaGel® BV phase 3 trials for the prevention of recurrent bacterial vaginosis – now expected to be available in late July/early August 2017.